Tags : Tanvex

Insights+

Insights+ Key Biosimilars Events of February 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of Feb, Biocon collaborated with CHAI to expand access […]Read More

Biosimilars

Tanvex Reports Results of TX05 (biosimilar, trastuzumab) in P-III Study

Shots: The P-III study evaluates the efficacy and safety of TX05 vs Herceptin (trastuzumab) in patients with human epidermal growth factor receptor 2-positive early breast cancer The 1EPs was an assessment of pCR following neoadjuvant therapy and definitive surgery in the per-protocol population Results: Patients achieved pCR (48.8% vs 45.3%) in the per-protocol population Click […]Read More